Short term simvastatin use in patients with systolic heart failure of ischemic origin did not preclude elevation of N-terminal pro-brain natriuretic peptide level

Kardiologiya

Volumn 46, Issue 12, 2006, Pages 12-16

  Smetanina, I N ^a   Vaulin, N A ^a   Masenko, V P ^a   Gratsiansky, N A ^a  

^a FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

Author keywords

Brain natriuretic peptide; Heart failure; Ischemic heart disease; Simvastatin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

BLOOD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HEART FAILURE;

CORONARY ARTERY DISEASE; HEART FAILURE, SYSTOLIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NATRIURETIC PEPTIDE, BRAIN; SIMVASTATIN;

EID: 33846407199     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Abulhul E., Spiers P., O'Loughlin C. et al. Statin therapy in patients with heart failure and normal cholesterol reduces brain natriuretic peptide. Eur Soc Cardiol Congress 2005; Abstract P1 065.
2. Node K., Fujita M., Kitakaze M. et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-843.
3. Bleske B.E., Nicklas J.M., Bard R.L. et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006;47:338-341.
4. Russian source
5. de Denus S., Pharand C., Williamson D.R. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 2004;125:652-668.
6. Cowie M.R., Jourdain P., Maisel A. et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-1718.
7. de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322.
8. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation 2002;105:2328-2331.
9. Hartmann F., Packer M., Coats A.J. et. al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004;110:1780-1786.
10. Bruins S., Fokkema M.R., Römer J.W. et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-2058.
11. Wu A.H., Smith A., Wieczoreh S. et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-631.
12. Davis M.E., Richards A.M., Nicholls M.G. et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006;21:977-985.
13. The RESOLVD Investigators. Effect of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000;101:378-384.
14. Luchner A., Burnett J.C., Jougasaki M. et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998;32:1839-1844.
15. Persson H., Andréasson K., Kahan T. et al. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail 2002;4:73-82.
16. Sanderson J.E., Chan W.W., Hung Y.T. et al. Effect of low dose beta blockers on atrial and ventricular (B-type) natriuretic factor in heart failure: a double blind, randomized comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;74:502-507.
17. Fung J.W., Yu C.M., Tip G. et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003;92:406-410.
18. Frantz R.P., Olson L.J., Grill D. et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005;149:541-547.
19. Stanek B., Frey B., Hülsmann M. et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-442.